Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment published : Today tags : Treatment save search
Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting
Published: 2024-04-24 (Crawled : 19:00) - biospace.com/
PGEN | $1.42 1.43% 1.41% 560K
|
Health Technology
|
| O: 0.0%
H: 2.14%
C: 1.43%
prgn-2012 respiratory asco treatment immunotherapy for meeting study
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
Published: 2024-04-24 (Crawled : 14:00) - globenewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: -1.05%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -0.05%
H: 0.97%
C: -0.04%
asco tumors treatment blood for
Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: 6.67%
H: 6.08%
C: 5.03%
fda opioid approval treatment for spray
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
ARWR | $23.285 -2.08% -2.13% 810K
|
Health Technology
|
| O: -0.17%
H: 0.08%
C: -1.9%
disease kidney treatment pharmaceuticals for study
United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism
Published: 2024-04-24 (Crawled : 13:00) - globenewswire.com
ASND | $143.14 -1.17% -1.18% 230K
|
Health Technology
|
| O: -0.57%
H: 1.67%
C: -0.57%
yorvipath treatment for
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
Published: 2024-04-24 (Crawled : 12:00) - biospace.com/
INVA | $15.15 -0.13% -0.13% 420K
|
Health Technology
|
| O: 1.03%
H: 0.72%
C: -0.13%
positive treatment global for
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
Published: 2024-04-24 (Crawled : 11:00) - globenewswire.com
ATAI | $1.875 -4.82% -5.07% 830K
|
Manufacturing
|
| O: -1.01%
H: 0.0%
C: -4.59%
bpl-003 first life depression treatment sciences study
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
Published: 2024-04-24 (Crawled : 11:00) - prnewswire.com
ALKS | $24.66 1.65% 1.62% 1.7M
|
Health Technology
|
| O: 0.43%
H: 2.27%
C: 1.61%
narcolepsy treatment for study
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
Published: 2024-04-24 (Crawled : 11:00) - globenewswire.com
HOOK | $0.843 10.2% 9.25% 10M
|
Health Technology
|
| O: 10.96%
H: 6.1%
C: 3.66%
hb-700 fda pharma drug treatment clearance for application
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Published: 2024-04-24 (Crawled : 11:00) - globenewswire.com
TVTX | $5.46 -4.88% -5.13% 2M
|
Health Technology
|
| O: -2.2%
H: 0.0%
C: -5.71%
filspari nephropathy treatment for therapeutics
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Published: 2024-04-24 (Crawled : 07:00) - prnewswire.com
AKBA | $1.36 -0.73% -0.74% 1.5M
|
Health Technology
|
| O: 0.0%
H: 2.19%
C: 0.0%
TVTX | $5.46 -4.88% -5.13% 2M
|
Health Technology
|
| O: -2.2%
H: 0.0%
C: -5.71%
filspari nephropathy treatment for therapeutics
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
Published: 2024-04-24 (Crawled : 05:00) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -0.36%
H: 0.05%
C: -0.15%
malaria positive treatment for novartis
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.